Literature DB >> 22605456

A sequential treatment algorithm for infants with stage 4s neuroblastoma and massive hepatomegaly.

Michael Weintraub1, Elisha Waldman, Benjamin Koplewitz, Allan I Bloom, Eitan Gross, Arnold I Freeman, Shoshana Revel-Vilk.   

Abstract

Infants with 4s neuroblastoma (NB) and massive hepatomegaly have a guarded prognosis and mortality approaches 30%. We report on eight patients with 4s NB and massive hepatomegaly treated with multiple modalities. One patient had spontaneous tumor regression. Three patients had progressive disease and responded to chemotherapy. Four patients progressed despite intravenous chemotherapy, of whom two died, and two were salvaged with hepatic intra-arterial chemoembolization. Treatment of infants with stage 4s NB with massive hepatomegaly should be individualized based on disease course. A sequential approach with observation, intravenous chemotherapy, and intra-arterial chemoembolization, may improve the outcome of these infants.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22605456     DOI: 10.1002/pbc.23186

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  4 in total

1.  A single center clinical analysis of children with neuroblastoma.

Authors:  Jing-Bo Shao; Zheng-Hua Lu; Wen-Yan Huang; Zhi-Bao Lv; Hui Jiang
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

2.  Hepatic metastatic disease in pediatric and adolescent solid tumors.

Authors:  Israel Fernandez-Pineda; John A Sandoval; Andrew M Davidoff
Journal:  World J Hepatol       Date:  2015-07-18

3.  Results of neuroblastoma treatment in Lithuania: a single centre experience.

Authors:  Austėja Juškaitė; Indrė Tamulienė; Jelena Rascon
Journal:  Acta Med Litu       Date:  2017

4.  Neonatal neuroblastoma with inferior vena cava syndrome.

Authors:  Serdar Alan; Ufuk Cakir; Dilek Kahvecioglu; Zulfikar Gordu; Omer Erdeve; Handan Dincaslan; Begum Atasay; Serdar Beken; Gulsan Yavuz; Saadet Arsan
Journal:  APSP J Case Rep       Date:  2013-05-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.